Soft quaternary anticholinergics: Comprehensive quantitative structure-activity relationship (QSAR) with a linearized biexponential (LinBiExp) model

Journal of Medicinal Chemistry

Volumn 49, Issue 3, 2006, Pages 883-891

  Buchwald, Peter ^a   Bodor, Nicholas ^a,b  

^a IVAX Research Inc   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT;

ANTICHOLINERGIC EFFECT; ARTICLE; BINDING SITE; LINEAR REGRESSION ANALYSIS; LINEARIZED BIEXPONENTIAL MODEL; MOLECULAR SIZE; NONHUMAN; NONLINEAR SYSTEM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOSPECIFICITY; STRUCTURE ANALYSIS;

ANIMALS; ATROPINE DERIVATIVES; GLYCOPYRROLATE; ILEUM; MODELS, MOLECULAR; MUSCARINIC ANTAGONISTS; N-METHYLSCOPOLAMINE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUATERNARY AMMONIUM COMPOUNDS; RABBITS; RECEPTOR, MUSCARINIC M3; REGRESSION ANALYSIS; STEREOISOMERISM;

EID: 32344437143     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050679n     Document Type: Article

References (72)

1. Barlow, R. B.; Berry, K. J.; Glenton, P. A.; Nilolaou, N. M.; Soh, K. S. A comparison of affinity constants for muscarine-sensitive acetylcholine receptors in guinea-pig atrial pacemaker cells at 29 °C and in ileum at 29 °C and 37 °C. Br. J. Pharmacol. 1976, 58, 613-620.
2. Birdsall, N. J. M.; Hulme, E. C. Muscarinic receptor subclasses. Trends Pharmacol. Sci. 1983, 4, 459-463.
3. Kubo, T.; Fukuda, K.; Mikami, A.; Maeda, A.; Takahashi, H.; Mishina, M.; Haga, T.; Haga, K.; Ichiyama, A.; Kangawa, K.; Kojima, M.; Matsuo, H.; Hirose, T.; Numa, S. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 1986, 323, 411-416.
4. Bonner, T. I.; Buckley, N. J.; Young, A. C.; Brann, M. R. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987, 237, 527-532.
5. Peralta, E. G.; Ashkenazi, A.; Winslow, J. W.; Smith, D. H.; Ramachandran, J.; Capon, D. J. Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987, 6, 3923-3929.
6. Bonner, T. I.; Young, A. C.; Brann, M. R.; Buckley, N. J. Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1988, 1, 403-410.
7. Caulfield, M. P.; Birdsall, N. J. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 1998, 50, 279-290.
8. 5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem. Res. 2003, 28, 437-442.
9. 3 antagonist discriminating against the other receptor subtypes. J. Med. Chem. 2002, 45, 984-987.
10. Wang, Y.; Chackalamannil, S.; Hu, Z.; Greenlee, W. J.; Clader, J.; Boyle, C. D.; Kaminski, J. J.; Billard, W.; Binch, H., III; Crosby, G.; Ruperto, V.; Duffy, R. A.; Cohen-Williams, M.; Coffin, V. L.; Cox, K. A.; Grotz, D. E.; Lachowicz, J. E. Improving the oral efficacy of CNS drug candidates: discovery of highly orally efficacious piperidinyl piperidine M2 muscarinic receptor antagonists. J. Med. Chem. 2002, 45, 5415-5418.
11. 1 muscarinic acetylcholine receptor are critical for ligand binding and the receptor activation switch. J. Biol. Chem. 2001, 276, 34098-34104.
12. Tanczos, A. C.; Palmer, R. A.; Potter, B. S.; Saldanha, J. W.; Howlin, B. J. Antagonist binding in the rat muscarinic receptor A study by docking and X-ray crystallography. Comput. Biol. Chem. 2004, 28, 375-385.
13. Eglen, R. M.; Watson, N. Selective muscarinic receptor agonists and antagonists. Pharmacol. Toxicol. 1996, 78, 59-68.
14. Brown, J. H.; Taylor, P. Muscarinic receptor agonists and antagonists. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed.; Hardman, J. G., Limbird, L. E., Eds.; McGraw-Hill: New York, 1996; pp 141-160.
15. 2-selective muscarinic receptor antagonists. J. Med. Chem. 2003, 46, 856-867.
16. Shelley, W. B.; Horvath, P. N. Comparative study on the effect of anticholinergic compounds on sweating. J. Invest. Dermatol. 1951, 16, 267-274.
17. MacMillan, F. S. K.; Reller, H. H.; Synder, F. H. The antiperspirant action of topically applied anticholinergics. J. Invest. Dermatol. 1964, 43, 363-377.
18. Stoughton, R. B.; Chiu, F.; Fritsch, W.; Nurse, D. Topical suppression of eccrine sweat delivery with a new anticholinegic agent. J. Invest. Dermatol. 1964, 42, 151-155.
19. Lasser, A. E. Results of a double-blind clinical study of a new anticholinergic agent as an axillary antiperspirant. III. Med. J. 1967, 131, 314-317.
20. Dolianitis, C.; Scarff, C. E.; Kelly, J.; Sinclair, R. Iontophoresis with glycopyrrolate for the treatment of palmoplantar hyperhidrosis. Australas. J. Dermatol. 2004, 45, 208-212.
21. Tashkin, D. P.; Cooper, C. B. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004, 125, 249-259.
22. Ali-Melkillä, T.; Kanto, J.; Iisalo, E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol. Scand. 1993, 37, 633-642.
23. Osterholm, R. K.; Camoriano, J. K. Transdermal scopolamine psychosis. J. Am. Med. Assoc. 1982, 247, 3081.
24. Birkhimer, L. J.; Jacobson, P. A.; Olson, J.; Goyette, D. M. Ocular scopolamine-induced psychosis. J. Fam. Pract. 1984, 18, 464-469.
25. Hamborg-Petersen, B.; Nielsen, M. M.; Thordal, C. Toxic effect of scopolamine eye drops in children. Acta Ophthalmol. (Copenhagen) 1984, 62, 485-488.
26. Merli, G. J.; Weitz, H.; Martin, J. H.; McClay, E. F.; Adler, A. G.; Fellin, F. M.; Libonati, M. Cardiac dysrhythmias associated with ophthalmic atropine. Arch. Intern. Med. 1986, 146, 45-47.
27. Fraunfelder, F. T. Mydriatics and cycloplegics. In Drug-Induced Ocular Side Effects and Drug Interactions, 3rd ed.; Fraunfelder, F. T., Meyer, S. M., Eds.; Lea & Febiger: New York, 1989; pp 445-458.
28. Khurana, A. K.; Ahluwalia, B. K.; Rajan, C.; Vohra, A. K. Acute psychosis associated with topical cyclopentolate hydrochloride. Am. J. Ophthalmol. 1988, 105, 91.
29. Wright, B.D. Exacerbation of akinetic seizures by atropine eye drops. Br. J. Ophthalmol. 1992, 76, 179-180.
30. Diamond, J. P. Systemic adverse effects of topical ophthalmic agents. Implications for older patients. Drugs Aging 1997, 11, 352-360.
31. Jayamanne, D. G.; Ray-Chaudhuri, N.; Wariyar, R.; Cottrell, D. G. Haemodynamic responses to subconjunctival mydriatic agents (Mydricaine) used for maintenance of perioperative mydriasis in patients undergoing vitreoretinal surgery. Eye 1998, 12, 792-794.
32. Bodor, N. Drug targeting and retrometabolic drug design approaches. Adv. Drug Delivery Rev. 1994, 14, 157-166.
33. Kumar, G. N.; Bodor, N. Soft anticholinergics. Curr. Med. Chem. 1996, 3, 23-36.
34. Bodor, N.; Buchwald, P. Retrometabolism-based drug design and targeting. In Burger's Medicinal Chemistry and Drug Discovery. Vol. 2, Drug Discovery and Drug Development, 6th ed.; Abraham, D. J., Ed.; Wiley: New York, 2003; pp 533-608.
35. Bodor, N.; Woods, R.; Raper, C.; Kearney, P.; Kaminski, J. Soft drugs. 3. A new class of anticholinergic agents. J. Med. Chem. 1980, 23, 474-480.
36. Brouillette, G.; Kawamura, M.; Kumar, G. N.; Bodor, N. Soft drugs. 21. Design and evaluation of soft analogues of propantheline. J. Pharm. Sci. 1996, 85, 619-623.
37. Hammer, R. H.; Amin, K.; Gunes, Z. E.; Brouillette, G.; Bodor, N. Novel soft anticholinergic agents. Drug Des. Delivery 1988, 2, 207-219.
38. Kumar, G. N.; Hammer, R. H.; Bodor, N. Soft drugs. 12. Design, synthesis, stability and evaluation of soft anticholinergics. Drug Des. Discovery 1993, 10, 11-21.
39. Kumar, G. N.; Hammer, R. H.; Bodor, N. S. Soft drugs. 16. Design, evaluation and transdermal penetration of novel soft anticholinergics based on methatropine. Bioorg. Med. Chem. 1993, 1, 327-332.
40. Huang, F.; Buchwald, P.; Browne, C. E.; Farag, H. H.; Wu, W.-M.; Ji, F.; Hochhaus, G.; Bodor, N. Receptor binding studies of soft anticholinergic agents. MPS PharmSci 2001, 3 (4), E30 (http:// www.pharmsci.org).
41. Hammer, R. H.; Gunes, E.; Kumar, G. N.; Wu, W.-M.; Srinivasan, V.; Bodor, N. S. Soft drugs. 14. Synthesis and anticholinergic activity of soft phenylsuccinic analogues of methatropine. Bioorg. Med. Chem. 1993, 1, 183-187.
42. Kumar, G. N.; Hammer, R. H.; Bodor, N. Soft drugs. 13. Design and evaluation of phenylsuccinic analogues of scopolamine as soft anticholinergics. Drug Des. Discovery 1993, 10, 1-9.
43. Juhász, A.; Huang, F.; Ji, F.; Buchwald, P.; Wu, W.-M.; Bodor, N. Design and evaluation of new soft anticholinergic agents. Drug Dev. Res. 1998,43, 117-127.
44. Ji, F.; Huang, F.; Juhasz, A.; Wu, W.; Bodor, N. Design, synthesis, and pharmacological evaluation of soft glycopyrrolate and its analog. Pharmazie 2000, 55, 187-191.
45. Ji, F.; Wu, W.-M.; Bodor, N. Studies on soft glycopyrrolate analogue, SG-1. Pharmazie 2002, 57, 138-141.
46. Huang, F.; Wu, W.-M.; Ji, F.; Juhász, A.; Bodor, N. Design, pharmacokinetic, and pharmacodynamic evaluation of soft anticholinergics based on tropyl α-phenylcyclopentyl acetate. Pharmazie 2002, 57, 115-121.
47. Huang, F.; Browne, C. E.; Wu, W.-M.; Juhász, A.; Ji, F.; Bodor, N. Design, pharmacokinetic, and pharmacodynamic evaluation of a new class of soft anticholinergics. Pharm. Res. 2003, 20, 1681-1689.
48. Ji, F.; Wu, W.; Dai, X.; Mori, N.; Wu, J.; Buchwald, P.; Bodor, N. Synthesis and pharmacological effects of new, N-substituted soft anticholinergics based on glycopyrrolate. J. Pharm. Pharmacol. 2005, 57, 1427-1436.
49. Wu, W.-M.; Buchwald, P.; Mori, N.; Ji, F.; Wu, J.; Bodor, N. Pharmacokinetic and pharmacodynamic evaluations of the zwitter-ionic metabolite of a new series of N-substituted soft anticholinergics. Pharm. Res. 2005, 22, 2035-2044.
50. Mori, N.; Buchwald, P.; Wu, W.-M.; Ji, F.; Bodor, N. Pharmacological effects of some newly developed soft anticholinergics and a receptor-binding QSAR study. Pharmazie, in press.
51. Buchwald, P. General linearized biexponential model for QSAR data showing bilinear-type distribution J. Pharm. Sci. 2005, 94, 2355-2379.
52. Kumar, G. N.; Huang, M.-J.; Hammer, R.; Bodor, N. Soft drugs. 17. Quantitative structure-activity relationships of soft anticholinergics based on methatropine and methscopolamine. J. Pharm. Sci. 1994, 83, 117-118.
53. Kubinyi, H. The quantitative analysis of structure-activity relationships. In Burger's Medicinal Chemistry and Drug Discovery, Wolff, M. E., Ed.; Wiley-Interscience: New York, 1995; Vol. 1, pp 497-571.
54. Buchwald, P.; Bodor, N. Soft glucocorticoid design: structural elements and physicochemical parameters determining receptor-binding affinity. Pharmazie 2004, 59, 396-404.
55. Buchwald, P.; Einstein, B.; Bodor, N. QSAR study of 2,3-benzodiazepin- 4(thi)one- and 1,2-phthalazine-related negative allosteric modulators of the AMPA receptor: a structural descriptors-based reassessment. QSAR Comb. Sci. 2005, 24, 325-331.
56. Barlow, R. B.; Franks, F. M.; Pearson, J. D. Studies on the stereospecificity of closely related compounds which block post-ganglionic acetylcholine receptors in the guinea-pig ileum. J. Med. Chem. 1973, 16, 439-446.
57. Pauling, P.; Datta, N. Anticholinergic substances: a single consistent conformation. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 708-712.
58. Turbanti, L.; Cerbai, G.; Garzelli, G.; Renzetti, A. R.; Criscuoli, M.; Subissi, A.; Bramanti, G.; Martinelli, A. N-Alkyl-nor-tropine esters of 2-phenyl-cyclohexenic acids as new bronchodilator agents. Effect of structural and conformational modifications on affinity for muscarinic receptors. Eur. J. Med. Chem. 1992, 27, 449-462.
59. Akaike, H. A new look at the statistical model identification. IEEE Trans. Autom. Control 1974, 19, 716-723.
60. Gabrielsson, J.; Weiner, D. Pharmacokinetic/Pharmacodynamic Data Analysis: Concepts and Applications. 3rd ed.; Apotekarsocieteten (Swedish Pharmaceutical Press): Stockholm, 2000; p 927.
61. Schwarz, G. Estimating the dimensions of a model. Ann. Stat. 1978, 6, 461.
62. Abramson, F. B.; Barlow, R. B.; Mustafa, M. G.; Stephenson, R. P. Relationships between chemical structure and affinity for acetylcholine receptors. Br. J. Pharmacol. 1969, 37, 207-233.
63. Lien, E. J.; Ariëns, E. J.; Beld, A. J. Quantitative correlations between chemical structure and affinity for acetylcholine receptors. Eur. J. Pharmacol. 1976, 35, 245-252.
64. Lambrecht, G.; Moser, U.; Mutschler, E. Example of a misprediction by using quantitative structure-activity relationships: On the spasmolytic activity of esters of xanthenylmandelic acid. Eur. J. Med. Chem. 1980, 15, 305-310.
65. 1-selective antimuscarinic tropinyl and piperidinyl esters. Eur. J. Pharm. Sci. 1999, 8, 39-47.
66. Chang, K. J.; Deth, R. C.; Triggle, D. J. Structural parameters determining cholinergic and anticholinergic activities in a series of 1,3-dioxolanes. J. Med. Chem. 1972, 15, 243-247.
67. Buchwald, P.; Bodor, N. Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J. Med. Chem. 1999, 42, 5160-5168.
68. Buchwald, P. Complexation thermodynamics of cyclodextrins in the framework of a molecular size-based model for nonassociative organic liquids that includes a modified hydration-shell hydrogen-bond model for water. J. Phys. Chem. B 2002, 106, 6864-6870.
69. Kubinyi, H. Quantitative structure-activity relationships. IV. Non-linear dependence of biological activity on hydrophobic character: a new model. Arzneim.-Forsch. 1976, 26, 1991-1997.
70. Kubinyi, H. Quantitative structure-activity relationships. 7. The bilinear model, a new model for nonlinear dependence of biological activity on hydrophobic character. J. Med. Chem. 1977, 20, 625-629.
71. Koelzer, P.; Biichi, J. Zusammenhange zwischen den physikalischchemischen Eigenschaften und der antimikrobiellen Wirksamkeit homologer aliphatischer Amine. 2. (Relations between physiochemical properties and antimicrobial activity of homologous aliphatic amines. 2) Arzneim.-Forsch. 1971, 21, 1721-1727.
72. Lien, E. J.; Wang, P. H. Lipophilicity, molecular weight, and drug action: reexamination of parabolic and bilinear models. J. Pharm. Sci. 1980, 69, 648-650.